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PURPOSE. To compare the effects of post-penetrating keratoplasty (PK) and post-keratopros-
thesis (KPro) surgery-related inflammation on the posterior segment of the eye and to assess
inhibition of tumor necrosis factor alpha (TNFa) and interleukin-1 beta (IL-1b) on these
effects.
METHODS. BALB/C (syngeneic) or C57BL/6 (allogeneic) corneas were transplanted onto BALB/
C host beds as part of PK or miniature KPro (m-KPro) implantation. Intraocular pressure (IOP)
was measured via an intracameral pressure sensor; tissues were harvested and analyzed 8
weeks after surgery. Expression of TNFa and IL-1b in the retina was analyzed using real-time
quantitative (q)PCR. Optic nerve degeneration (axon count, circularity, and area) was
assessed quantitatively using ImageJ software. After m-KPro implantation, mice were treated
with saline, anti-TNFa, or anti-IL-1b antibody, and axonal loss was assessed after 10 weeks.
RESULTS. Mean IOP was within normal limits in the operated and fellow eyes in all groups. The
mRNA expression of TNFa and IL-1b was highest in m-KPro groups with either syngeneic or
an allogeneic carrier. We observed optic nerve degeneration in both allogeneic PK and m-
KPro implanted eyes with an allogeneic carrier. However, TNFa blockade significantly
reduced axonal loss by 35%.
CONCLUSIONS. Allogeneic PK and m-KPro implants with an allogeneic carrier lead to chronic
inflammation in the posterior segment of the eye, resulting in optic nerve degeneration. In
addition, blockade of TNFa prevents axonal degeneration in this preclinical model of
allogeneic m-KPro (alloKPro) implantation.
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Penetrating keratoplasty (PK) and Boston keratoprosthesis(B-KPro) implantation are sight-saving procedures in many
patients with corneal blindness. The vast majority of corneal
donor tissues for PK and corneas used as a B-KPro carrier are
allogeneic and are derived from a genetically nonidentical
donor. Recent data on PK have demonstrated guarded long-
term survival rates for several disease categories, including
Fuchs endothelial dystrophy and pseudophakic bullous kera-
topathy, as well as in regrafts.1,2
Allograft rejection, late endothelial failure, postgraft infec-
tion, and glaucoma are the most common causes for graft
failure after PK.2 Boston keratoprosthesis, the most widely used
artificial cornea, consists of a polymethylmethacrylate (PMMA)
front plate and a PMMA or titanium back plate supported by a
donor corneal transplant, and can be used when standard PK is
expected to yield a poor prognosis. Keratoprosthesis with a
PMMA back plate is the most commonly implanted KPro design
outside the Massachusetts Eye and Ear Infirmary (MEEI);
however, the newest design with titanium back plate has been
used at MEEI since 2005.3 The titanium back plate is thinner,
causing less crowdedness of the anterior chamber of the eye,
and titanium is known to cause less inflammation in the tissue
than PMMA.3,4 More than 50% of all patients receiving B-KPros
retain good vision after 7 years, but these patients can also
experience long-term complications such as retroprosthesis
membrane, glaucoma, sterile corneal necrosis, optic neuropa-
thy, retinal detachment, chronic macular edema, and choroidal
detachment.5–8
Using a miniature-KPro model (m-KPro),9 our group recently
reported increased chronic inflammation in the cornea after
allogeneic PK and m-KPro implants with an allogeneic carrier.10
These changes may lead to anterior segment complications
such as allograft rejection or late endothelial failure in PK or
retroprosthesis membrane and sterile corneal necrosis in KPro.
It is known that cytokines play a critical role in promoting
inflammation in corneal transplantation11; however, the effect
of inflammation in the anterior eye on posterior changes and
long-term complications in B-KPro patients remains largely
unknown. In this study, we hypothesize that allogeneic PK and
m-KPro implantation with an allogeneic carrier not only cause
anterior segment inflammation but also chronic changes in the
posterior segment of the eye (not tissue-restricted immune
response).
Here, we assessed inflammation and associated damage to
the posterior part of murine eyes after performing PK and m-
KPro implantation using allogeneic or syngeneic corneal tissue.
We analyzed the expression of TNFa and IL-1b in the retina
after PK and m-KPro implantation, and evaluated whether
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blockade of TNFa or IL-1b can reduce optic nerve degenera-
tion. For the first time, we shed light on potential mechanisms
of posterior segment complications after PK and KPro
implantation.
METHODS
Animals
A total of 125 male mice (8–10 weeks old; Jackson Laboratory,
Bar Harbor, ME, USA; 82 BALB/C as recipients; 10 BALB/C and
28 C57BL/6 as donors; and 11 as na¨ıve) were used in this
study. Mice were housed in a climate-controlled animal facility
at the Schepens Eye Research Institute, Massachusetts Eye and
Ear, Harvard Medical School (Boston, MA, USA), and kept
under cyclic light conditions (12 hours on/off). All animal
experiments were approved by the Institutional Animal Care
and Use Committee and were conducted in accordance with
the ARVO Statement for the Use of Animals in Ophthalmic and
Vision Research.
For the first part of the study, mice were divided into five
groups (10 mice/group): (1) na¨ıve, (2) syngeneic penetrating
keratoplasty (synPK) (BALB/C donor cornea transplanted to
BALB/C recipient), (3) allogeneic penetrating keratoplasty
(alloPK) (C57BL/6 donor cornea transplanted to BALB/C
recipient), (4) syngeneic m-KPro implantation (synKPro)
(BALB/C carrier corneal graft with assembled m-KPro trans-
planted to BALB/C recipient), and (5) allogeneic m-KPro
implantation (alloKPro) (C57BL/6 carrier corneal graft with
assembled m-KPro transplanted to BALB/C recipient).
Second, to analyze the effect of cytokine inhibition,
alloKPro implantation was performed. After implantation,
mice were divided into four groups and treated with saline,
anti-TNFa, or anti-IL-1b antibody or kept untreated. Intraperi-
toneal saline, anti-TNFa antibody (10 mg/kg), or anti-IL-1b
antibody (10 mg/kg) was administered once a week starting at
day 0 through week 10. The mice were analyzed 10 weeks
after the procedure.
Penetrating Keratoplasty
Surgeries were performed under a surgical microscope (Zeiss,
Jena, Germany). Procedures were performed by two investiga-
tors (MO and AC). After euthanasia of the donor mice, corneas
were marked with a 2-mm-diameter biopsy punch (Miltex,
Plainsboro, NJ, USA). To maintain a deep anterior chamber,
viscoelastic (Viscoat; Alcon, Irvine, CA, USA) was injected
through the groove with a 30-gauge cannula (Rumex, Clear-
water, FL, USA). Corneas were excised with Vannas scissors
(Storz Instruments Company, San Damis, CA, USA) and placed
in phosphate-buffered saline (PBS) until the host corneal bed
had been prepared.
Recipient mice were anesthetized by intraperitoneal
injection of ketamine (120 mg/kg) and xylazine (20 mg/kg).
A drop of 1% tropicamide (Bausch & Lomb, New York, NY,
USA) and a drop of 0.5% phenylephrine hydrochloride (Altaire
Pharmaceuticals, New York, NY, USA) were applied to the right
eye to dilate the pupil 15 minutes before the procedure.
Corneas were marked with a 2-mm-diameter biopsy punch
(Harris UniCore punch; Ted Pella, Inc., Redding, CA, USA).
Before opening the eye, viscoelastic (Viscoat, Alcon) was
injected via a 30-gauge cannula (Rumex, Clearwater, FL, USA).
The cornea was excised with Vannas scissors (Storz Instru-
ments Company). Throughout the procedure, viscoelastic was
used to maintain the depth of the anterior chamber. The host
lens was removed as previously described.12 Briefly, a
curvilinear continuous capsulorrhexis was performed with
jeweler forceps (Katena, Denville, NJ, USA), and a hydro-
dissection was performed with a 30-gauge cannula and PBS to
deliver the lens en bloc. Visible cortex remnants were carefully
aspirated through the cannula. The donor cornea was then
placed in the recipient bed and secured with eight interrupted
11-0 nylon sutures (Sharpoint; Angiotech Pharmaceuticals,
Vancouver, Canada) in standard PK fashion.
Miniature KPro Implantation
A miniature keratoprosthesis (m-KPro) (JG Machine, Wilming-
ton, MA, USA), minimized, but otherwise identical to the B-
KPro device used in humans, was used. It consists of a PMMA
front plate with central stem and a titanium (Ti) back plate
with eight peripheral holes. The diameters of the front and
back plate were 1.0 and 1.3 mm, respectively. The design
description and the exact dimensions of the m-KPro are
described elsewhere.9 The surgical procedure was performed
similarly to B-KPro implantation in humans and has been
described previously.9
Briefly, to prepare for the assembly of the m-KPro device,
excised donor corneas were trephined centrally with a 0.5-mm-
diameter punch (Harris UniCore punch, Ted Pella, Inc.) and
then slid over the stem of the PMMA front plate. The titanium
back plate was positioned and locked on the stem such that
the donor cornea became securely sandwiched between the
front and back plates. The donor–device complex was then
placed in PBS until the host corneal bed had been prepared as
described above. After preparation, the donor cornea–m-KPro
complex was placed in the recipient bed and secured with
eight interrupted 11-0 nylon sutures (Sharpoint, Angiotech
Pharmaceuticals) in standard PK fashion.
Postoperative Treatment
In the first part of the study, postoperative treatment was
identical after PK and m-KPro implantation. One drop of 1%
corticosteroid (Pred Forte; Allergan, Irvine, CA, USA) and
antibiotic ointment (AK-POLY-BAC; Akorn, Lake Forest, IL,
USA) were applied immediately after the procedure, and a
tarsorrhaphy was performed using 8-0 nylon sutures (Shar-
point, Angiotech Pharmaceuticals). Corticosteroid was admin-
istered once a day for 2 weeks and then every other day for 2
weeks. The tarsorrhaphy was removed 48 hours after the
surgery, and corneal sutures were removed 1 week following
surgery. Per standard institutional animal care and use
protocols, 0.1 mg/kg buprenorphine (Reckitt Benckiser
Healthcare Ltd., Hull, England) was applied subcutaneously
after the procedure and every 12 hours for 48 hours
postoperatively. The mice were euthanized 8 weeks after the
procedure for further analysis. Eight weeks in mice corre-
sponds to around 6 years in humans.13
In the second part of the study, corticosteroids were not
used and mice were euthanized 10 weeks after the procedure;
the rest of the postoperative treatment was identical to that for
the first part.
Intraocular Pressure (IOP) Measurement
To evaluate IOP after syngeneic or allogeneic PK and m-KPro
implantation, direct manometry was used. Intracameral IOP
measurements were performed in anesthetized mice using a
custom-designed 32-gauge needle electromechanical pressure
sensor. Measurements were performed by inserting the needle
in the anterior chamber of the eye through a clear cornea
puncture. Intraocular pressure readings were stored in a
personal computer for further analysis.
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Reverse Transcription and Real-Time PCR
Retinas were harvested at 8 weeks post surgery. RNA was
isolated with the RNeasy Micro Kit (Qiagen, Valencia, CA, USA)
and reverse transcribed using Superscript III Kit (Invitrogen,
Grand Island, NY, USA). Real-time quantitative (q)PCR was
performed using Taqman Universal PCR Mastermix and
preformulated primers for murine glyceraldehyde 3-phosphate
dehydrogenase (GAPDH), tumor necrosis factor alpha (TNFa),
and interleukin-1 beta (IL-1b) (Applied Biosystems, Foster City,
CA, USA). The results were normalized to the expression level
in na¨ıve mice and were analyzed by the comparative threshold
cycle method, using GAPDH as an internal control. Real-time
PCR was repeated twice for each cytokine. Retinas of three
mice were pooled and duplicates for each group were
analyzed.
Optic Nerve Axon Counts, Circularity, and Area
Optic nerves were analyzed as described before.14 Briefly,
optic nerves were fixed with half-strength Karnovsky fixative
and cut into 1-lm cross sections. Pictures of five cross
sections were taken with 320 magnification under a light
microscope to determine optic nerve perimeter. Five pictures
of each cross section were taken with3100 magnification to
quantify axon numbers per mm2 and axon size. The pictures
were systematically analyzed using ImageJ (National Institutes
of Health, Bethesda, MD, USA). Circularity was defined as
4p3[Area]/[Perimeter]2 with a value of 1.0 indicating a
perfect circle. As the value approaches 0.0, it indicates an
increasingly noncircular shape.
Statistics
Student’s t-test was used to analyze the data. P  0.05 was
considered statistically significant. Results are presented as the
mean 6 standard error of the mean (SEM).
RESULTS
Intraocular Pressure After Syngeneic or Allogeneic
PK and m-KPro Implantation
We measured IOP in the operated and fellow eyes of mice after
syngeneic or allogeneic PK and m-KPro implantation and in the
eyes of na¨ıve mice. All groups showed a similar mean IOP
within normal limits (14–19 mm Hg). There was no statistically
significant difference between any of the experimental groups
(Fig. 1).
Inflammatory Cytokine Expression in the Retina
After Syngeneic or Allogeneic PK and m-KPro
To evaluate inflammation in the retina following PK and m-
KPro implantation, we quantified mRNA expression of the
proinflammatory cytokines TNFa and IL-1b at week 8 after
surgery. We detected an increase in TNFa expression in all
operated groups compared to na¨ıve mice; however, a
significant increase was seen only in the synKPro (P < 0.01)
and alloKPro (P < 0.05) groups (Fig. 2A). The expression of IL-
1b was higher in syngeneic and allogeneic m-KPro groups
compared to syngeneic and allogeneic PK groups, respectively
(Fig. 2B). The alloKPro group showed significantly higher
expression of IL-1b compared to na¨ıve mice (P < 0.05; Fig. 2B).
Optic Nerve Axon Count, Size, and Circularity After
Syngeneic or Allogeneic PK and m-KPro
Implantation
To determine the effect of PK and m-KPro implantation on
optic nerve changes, we analyzed optic nerve images from
week 8 after surgery with ImageJ (Figs. 3A, 3B). The number of
axons remained similar in the synPK and synKPro groups
compared to the fellow eye. However, we observed axon loss
of 13 6 8% and 19 6 8% in the alloPK and alloKPro groups,
respectively (Fig. 3C). We additionally analyzed axon size and
circularity. Average axon size increased in all operated groups
compared to na¨ıve mice (Fig. 3D). Axon circularity was
reduced in all four groups compared to na¨ıve mice and
significantly reduced in the alloKPro group (Fig. 3E).
FIGURE 1. Intraocular pressure measurements in mice. Intraocular
pressure was measured in the operated and fellow eyes using
manometry 8 weeks post surgery. N, na¨ıve; synPK, syngeneic PK;
synKPro, syngeneic m-KPro; alloPK, allogeneic PK; and alloKPro,
allogeneic m-KPro. n ¼ 5/group.
FIGURE 2. Quantification of proinflammatory cytokines in the retina. Transplant recipients from all groups (syngeneic [syn] and allogeneic [allo]
penetrating keratoplasty [PK] and miniature-Boston keratoprosthesis [m-KPro]) were euthanized at 8 weeks post surgery and retinas were collected
and analyzed for the expression of (A) TNFa and (B) IL-1b by real-time qPCR. n ¼ 6/group; *P ¼ 0.05; **P < 0.05. Data from one representative
experiment of two is shown. N, na¨ıve; synPK, syngeneic PK; synKPro, syngeneic m-KPro; alloPK, allogeneic PK; and alloKPro, allogeneic m-KPro.
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TNFa Blockade Protects the Optic Nerve After
Allogeneic m-KPro
To determine the protective effect of TNFa and IL-1b blockade
on optic nerve degeneration, anti-TNFa or anti-IL-1b antibody
was administered after alloKPro implantation. We quantified
optic nerve axon numbers 10 weeks after the surgery. Control
mice that had m-KPro implantation (treated only with saline)
had a reduction of 29 6 4% in axon numbers compared to
unoperated eyes. Similarly, m-KPro mice treated with anti-IL-1b
antibody had an associated axon loss of 29 6 1% compared to
unoperated mice, indistinguishable from the saline control
group (Fig. 4; P ¼ 0.96). In contrast, m-KPro mice that were
treated with anti-TNFa antibody experienced axon loss of only
19 6 1%, a 35% reduction in axon loss compared to the saline-
treated m-KPro implanted mice (P ¼ 0.03).
DISCUSSION
The etiologies of chronic complications after PK and B-KPro
surgery such as late endothelial failure, optic neuropathy,
epiretinal membrane, macular edema, and retinal detachment
remain largely unknown. And, for undetermined reasons,
unusually rapid progression of glaucoma can be observed in
PK15 as well as in KPro patients.16,17 It is known that anterior
segment injuries and procedures like corneal burn or lens
removal can induce posterior segment inflammation and
damage.18,19 This is most likely caused by posterior diffusion
of inflammatory cytokines secreted in the injured anterior
segment.20 We have recently shown increased TNFa and IL-1b
expression in the cornea after allogeneic PK and m-KPro
implantation with allogeneic carrier.10 Increased TNFa pro-
FIGURE 3. Quantification of optic nerve axon loss and axon circularity and size in mice. (A) Representative electron microscopy images taken from
p-phenylenediamine–stained optic nerve sections of na¨ıve (N), syngeneic PK (synPK), syngeneic m-KPro (synKPro), allogeneic PK (alloPK), and
allogeneic m-KPro (alloKPro) mice. Scale bar: 20 lm. (B) Representative images showing the analysis with ImageJ. Quantification (as percentage) of
axon loss compared to the fellow eye (C), axon average size (D), and axon circularity (E) at 8 weeks postoperatively is shown. A value of 1.0
indicates a perfect circle; as the value approaches 0.0, it indicates an increasingly noncircular shape. n¼ 6/group; ***P < 0.01.
FIGURE 4. Quantification of optic nerve axon loss in saline-, anti-
TNFa–, and anti-IL-1b–treated alloKPro implanted mice. After alloge-
neic m-KPro implantation, mice were treated with saline, anti-TNFa (10
mg/kg), or anti-IL-1b (10 mg/kg) antibody, and axon loss (as percentage
compared to na¨ıve mice) was assessed after 10 weeks using Karnovsky
fixative and ImageJ. n¼ 6/group; P ¼ 0.03.
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duction has been also associated with high IOP and with optic
nerve degeneration in murine models of glaucoma.21 In our
study, mean IOP was within normal limits, although some eyes
had high IOP, and peak values of IOP might not have been
detected by a one-time measurement.
With this in mind, we analyzed the extent of retinal
inflammation and optic nerve damage following PK and m-
KPro surgery in order to elucidate a mechanism by which
postoperative complications arise after such procedures. We
observed increased retinal inflammation by measuring proin-
flammatory cytokine expression. We detected increased mRNA
TNFa expression in the retina after alloPK as well as after
synKPro and alloKPro compared to na¨ıve and synPK. The
mRNA expression of IL-1b was higher after synKPro and
alloKPro compared with the synPK and alloPK groups,
respectively, a pattern that is consistent with the expression
of inflammatory cytokines seen in our previous study.10 By
comparing retinal inflammation after syngeneic and allogeneic
PK and m-KPro implantation, we found that both the
allogeneic carrier graft and the m-KPro device contribute to
chronic inflammation of the posterior segment.
We further analyzed optic nerve degeneration and found
similar axon numbers in operated eyes of both syngeneic
groups (synPK and synKPro) compared with the fellow,
nonoperated eye, but we observed axon loss in the alloPK
and the alloKPro groups compared to fellow eyes. During
degeneration, axons first swell and bead,22 then decrease in
their caliber and lose circularity.23–25 In our study, we found
that the axon size slightly increased in the synPK, alloPK, and
synKPro groups, but remained comparable to na¨ıve in the
alloKPro group. Additionally, we found reduced circularity in
all operated groups compared to na¨ıve mice, with a
significant difference in the alloKPro group. These results
suggest an ongoing degenerative process of the optic nerve in
the chronic postoperative period in operated eyes, which is
more pronounced after alloKPro implantation. Blocking
TNFa, but not IL-1b, in alloKPro implanted mice had a
significant protective effect on axon loss, similar to the
reported protective effect of TNFa blockade in preclinical
models of glaucoma.21 While TNFa antagonists could prove a
new strategy to protect against chronic damage to the
posterior segment after KPro implantation or repeated
transplants, we would caution against any generalization
derived from our data in regard to this treatment strategy.
Rather, we believe that controlled studies evaluating the
efficacy and toxicity/safety of anti-TNFa strategies for
suppressing optic neuropathy in highly inflamed eyes that
undergo keratoplasty or KPro surgery are warranted before
any recommendations are made in relation to specific
therapeutic approaches.
In summary, this study provides the first insights into the
mechanisms by which KPro implantation may lead to optic
nerve damage, and supports the anecdotal reports of rapid and
progressive optic neuropathy after KPro implantation. Our
data further suggest that corneal allogenicity and the KPro
device itself both contribute to the chronic inflammation,
affect the posterior segment of the eye, and affect the resultant
optic neuropathy. The validation of reducing carrier tissue
allogenicity (e.g., via gamma irradiation),26 or cytokine
blockade to reduce optic neuropathy after KPro will require
clinical trial confirmation.
Acknowledgments
The authors thank Susanne Eiglmeier (Schepens Eye Research
Institute, Massachusetts Eye and Ear Infirmary, Boston) for helpful
scientific discussions and for providing editorial assistance in the
preparation of thismanuscript; Demetrios Vavvas (Massachusetts Eye
and Ear Infirmary, Boston) for scientific advice; Pavlina Tsoka, Miin
(Irene) Roh (Massachusetts Eye and Ear Infirmary, Boston), Kishore
Katikireddy, and Antonio di Zazzo (Schepens Eye Research Institute,
Boston) for advice and help in analyzing retinas and optic nerves.
Supported by the Boston-KPro research fund and National
Institutes of Health Grant R01-EY 12963.
Disclosure: A. Cˇrnej, Massachusetts Eye and Ear Infirmary (E); M.
Omoto, Massachusetts Eye and Ear Infirmary (E); T.H. Dohlman,
Massachusetts Eye and Ear Infirmary (E); M. Gonzalez-Andrades,
Massachusetts Eye and Ear Infirmary (E); E.I. Paschalis, Massa-
chusetts Eye and Ear Infirmary (E); A. Cruzat, Massachusetts Eye
and Ear Infirmary (E); T.H.K. Vu, Massachusetts Eye and Ear
Infirmary (E); M. Doorenbos, Massachusetts Eye and Ear
Infirmary (E); D.F. Chen, Massachusetts Eye and Ear Infirmary
(E); C.H. Dohlman, Massachusetts Eye and Ear Infirmary (E); R.
Dana, Massachusetts Eye and Ear Infirmary (E)
References
1. Al-Mezaine H, Wagoner MD; King Khaled Eye Specialist
Hospital Cornea Transplant Study Group. Repeat penetrating
keratoplasty: indications, graft survival, and visual outcome. Br
J Ophthalmol. 2006;90:324–327.
2. Tan DTH, Janardhanan P, Zhou H, et al. Penetrating
keratoplasty in Asian eyes: the Singapore Corneal Transplant
Study. Ophthalmology. 2008;115:975–982, e1.
3. Todani A, Ciolino JB, Ament JD, et al. Titanium back plate for a
PMMA keratoprosthesis: clinical outcomes. Graefes Arch Clin
Exp Ophthalmol. 2011;249:1515–1518.
4. Overgaard L, Danielsen N, Bjursten LM. Anti-inflammatory
properties of titanium in the joint environment. An experi-
mental study in rats. J Bone Joint Surg Br. 1998;80:888–893.
5. Srikumaran D, Munoz B, Aldave AJ, et al. Long-term outcomes
of boston type 1 keratoprosthesis implantation. Ophthalmol-
ogy. 2014;121:2159–2164.
6. Ciolino JB, Belin MW, Todani A, Al-Arfaj K, Rudnisky CJ; Boston
Keratoprosthesis Type 1 Study Group. Retention of the Boston
keratoprosthesis type 1: multicenter study results. Ophthal-
mology. 2013;120:1195–1200.
7. Modjtahedi BS, Eliott D. Vitreoretinal complications of the
Boston Keratoprosthesis. Semin Ophthalmol. 2014;29:338–
348.
8. Aldave AJ, Sangwan VS, Basu S, et al. International results with
the Boston type I keratoprosthesis. Ophthalmology. 2012;119:
1530–1538.
9. Crnej A, Omoto M, Dohlman TH, et al. A novel murine model
for keratoprosthesis. Invest Ophthalmol Vis Sci. 2014;55:
3681–3685.
10. Crnej A, Omoto M, Dohlman TH, Dohlman CH, Dana R.
Corneal inflammation after miniature keratoprosthesis implan-
tation. Invest Ophthalmol Vis Sci. 2015;56:185–189.
11. Amouzegar A, Chauhan SK, Dana R. Alloimmunity and
tolerance in corneal transplantation. J Immunol. 2016. In
press.
12. Kurihara T, Omoto M, Noda K, et al. Retinal phototoxicity in a
novel murine model of intraocular lens implantation. Mol Vis.
2009;15:2751–2761.
13. Miller RA, Nadon NL. Principles of animal use for gerontolog-
ical research. J Gerontol A Biol Sci Med Sci. 2000;55:B117–
B123.
14. Yang Q, Cho KS, Chen H, et al. Microbead-induced ocular
hypertensive mouse model for screening and testing of
aqueous production suppressants for glaucoma. Invest Oph-
thalmol Vis Sci. 2012;53:3733–3741.
15. Rumelt S, Bersudsky V, Blum-Hareuveni T, Rehany U.
Preexisting and postoperative glaucoma in repeated corneal
transplantation. Cornea. 2002;21:759–765.
Effect of PK and KPro Implant on Posterior Segment IOVS j April 2016 j Vol. 57 j No. 4 j 1647
16. Crnej A, Paschalis EI, Salvador-Culla B, et al. Glaucoma
progression and role of glaucoma surgery in patients with
Boston keratoprosthesis. Cornea. 2014;33:349–354.
17. Kamyar R, Weizer JS, de Paula FH, et al. Glaucoma associated
with Boston type I keratoprosthesis. Cornea. 2012;31:134–
139.
18. Cade F, Paschalis EI, Regatieri CV, Vavvas DG, Dana R, Dohlman
CH. Alkali burn to the eye: protection using TNF-a inhibition.
Cornea. 2014;33:382–389.
19. Xu H, Chen M, Forrester JV, Lois N. Cataract surgery induces
retinal pro-inflammatory gene expression and protein secre-
tion. Invest Ophthalmol Vis Sci. 2011;52:249–255.
20. Nakazawa T, Nakazawa C, Matsubara A, et al. Tumor necrosis
factor-alpha mediates oligodendrocyte death and delayed
retinal ganglion cell loss in a mouse model of glaucoma. J
Neurosci. 2006;26:12633–12641.
21. Roh M, Zhang Y, Murakami Y, et al. Etanercept, a widely used
inhibitor of tumor necrosis factor-a (TNF-a), prevents retinal
ganglion cell loss in a rat model of glaucoma. PLoS One. 2012;
7:e40065.
22. Gaudet AD, Popovich PG, Ramer MS. Wallerian degeneration:
gaining perspective on inflammatory events after peripheral
nerve injury. J Neuroinflammation. 2011;8:110.
23. Sievers C, Platt N, Perry VH, Coleman MP, Conforti L. Neurites
undergoing Wallerian degeneration show an apoptotic-like
process with Annexin V positive staining and loss of
mitochondrial membrane potential. Neurosci Res. 2003;46:
161–169.
24. Buckmaster EA, Perry VH, Brown MC. The rate of Wallerian
degeneration in cultured neurons from wild type and C57BL/
WldS mice depends on time in culture and may be extended in
the presence of elevated Kþ levels. Eur J Neurosci. 1995;7:
1596–1602.
25. Pullarkat PA, Dommersnes P, Ferna´ndez P, Joanny J-F, Ott A.
Osmotically driven shape transformations in axons. Phys Rev
Lett. 2006;96:048104.
26. Stevenson W, Cheng S-F, Emami-Naeini P, et al. Gamma-
irradiation reduces the allogenicity of donor corneas. Invest
Ophthalmol Vis Sci. 2012;53:7151–7158.
Effect of PK and KPro Implant on Posterior Segment IOVS j April 2016 j Vol. 57 j No. 4 j 1648
